A class action lawsuit has been initiated against Mereo BioPharma Group plc, alleging the company issued materially false and misleading statements regarding its clinical development programs. The litigation centers on the company's Phase 3 ORBIT and COSMIC clinical trials, which reportedly failed to meet their primary endpoints, potentially impacting the company's pipeline and investor valuations.
Investors who acquired Mereo securities during the period spanning June 5, 2023 through December 26, 2025 may be eligible to participate in the class action. The case represents an effort to hold the company accountable for alleged disclosure failures during a critical period of clinical development.
The deadline for investors to be designated as lead plaintiff in the action is April 6, 2026. Class action lawsuits of this nature typically require demonstration that investors suffered financial losses based on reliance on the company's public statements. Interested parties should consult with legal counsel regarding eligibility and the process for joining the litigation.